Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
The CDC issued a report that supports earlier findings, stating that the efficacy of this year's flu vaccine is low.
Researchers associated with the Mount Sinai Health System believe that a universal flu vaccine could be closer to development.
The U.S. Food and Drug Administration (FDA) has approved RAPIVAB, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
The Centers for Disease Control and Prevention (CDC) issued a health warning about the current flu vaccine.
Those same experts report the flu vaccine is safe for patients who have not had a stem cell transplant.
People with weakened immune systems due to cancer are at increased risk of severe complications from the influenza virus, according to experts.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|